Verona Pharma Ltd의 수익 품질 점수는 B+/45.572918입니다. 이 점수는 수익성, 성장, 현금 창출 및 자본 배분, 레버리지의 네 가지 차원을 기반으로 합니다.
Verona Pharma Ltd는 언제 수익을 보고하나요?
Verona Pharma Ltd의 다음 수익 보고서는 2026-04-05에 발표될 예정입니다.
Verona Pharma Ltd의 예상 수익은 얼마인가요?
월스트리트 애널리스트에 따르면 Verona Pharma Ltd의 예상 수익은 $130.79M입니다.
Verona Pharma Ltd은 수익 기대치를 충족했나요?
Verona Pharma Ltd의 최근 수익은 $로, 기대치를 .
주요 통계
이전 종가
$106.79
시가
$106.91
일일 범위
$106.91 - $106.91
52주 범위
$47.2 - $106.93
거래량
1.8M
평균 거래량
2.8M
배당수익률
--
EPS(TTM)
-0.12
시가총액
$9.1B
VRNA란 무엇인가요?
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The firm has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. The company has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The firm's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
